Фармакоэкономическая оценка использования эритропоэтинов у онкологических больных с анемией

А. Ю. Куликов, Крысанов Иван Сергеевич · Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология · 2009

A number researches of pharmacoeconomics of hemotransfusion and rEPO drugs at oncological patients with anemia have been published. It is necessary to note, that the majority of publications on the topic are foreign. Thus there are no researches, comparing pharmacoeconomic efficiency of various rEPO among themselves, including the researches conducting in Russia. Results: As a result of the analysis of «willingness-to-pay» it has been determined, that for the prolonged regimens of dosing in duration of 16 weeks at value of a threshold «willingness-to-pay» more, than 60 000 rbl. the therapy with Eprex® 40000 once a week is most cost-effective. For Eprex® 10000 the optimum «cost-effectiveness» ratio is observed at any values of a threshold «willingness-to-pay», Recormon® 10000 and Aranesp ™ 2,25 mkg/kg at such regimens of dosing will be less «cost-effective». Results of budget-impact analysis show, that Eprex® application in dosages 10000 and 40000 is more «cost-effective» in comparison with Recormon® and Aranesp in a number of regions. Conclusions: During the analysis convincing advantages of Eprex 10000 use three times a week and 40000 once a week for correction of anemia at oncological patients in conditions of the Russian system of public health services have been shown.

Cited by 0 works.

Authors